267 related articles for article (PubMed ID: 34750509)
1. Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.
Bajrami I; Walker C; Krastev DB; Weekes D; Song F; Wicks AJ; Alexander J; Haider S; Brough R; Pettitt SJ; Tutt ANJ; Lord CJ
Commun Biol; 2021 Nov; 4(1):1270. PubMed ID: 34750509
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
[TBL] [Abstract][Full Text] [Related]
4. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
6. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
7. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Mengwasser KE; Adeyemi RO; Leng Y; Choi MY; Clairmont C; D'Andrea AD; Elledge SJ
Mol Cell; 2019 Mar; 73(5):885-899.e6. PubMed ID: 30686591
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Zhu Q; Han SX; Zhou CY; Cai MJ; Dai LP; Zhang JY
Oncotarget; 2015 May; 6(13):11575-84. PubMed ID: 25865228
[TBL] [Abstract][Full Text] [Related]
9. [Poly(ADP-Ribose) Polymerases 1 and 2: Classical Functions and Interaction with New Histone Poly(ADP-Ribosyl)ation Factor HPF1].
Kurgina TA; Lavrik OI
Mol Biol (Mosk); 2023; 57(2):254-268. PubMed ID: 37000654
[TBL] [Abstract][Full Text] [Related]
10. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
Ding X; Ray Chaudhuri A; Callen E; Pang Y; Biswas K; Klarmann KD; Martin BK; Burkett S; Cleveland L; Stauffer S; Sullivan T; Dewan A; Marks H; Tubbs AT; Wong N; Buehler E; Akagi K; Martin SE; Keller JR; Nussenzweig A; Sharan SK
Nat Commun; 2016 Aug; 7():12425. PubMed ID: 27498558
[TBL] [Abstract][Full Text] [Related]
11. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
12. Exploiting replication gaps for cancer therapy.
Cong K; Cantor SB
Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
[TBL] [Abstract][Full Text] [Related]
13. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
Helleday T
Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475
[TBL] [Abstract][Full Text] [Related]
14. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.
Ying S; Hamdy FC; Helleday T
Cancer Res; 2012 Jun; 72(11):2814-21. PubMed ID: 22447567
[TBL] [Abstract][Full Text] [Related]
15. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Gogola E; Duarte AA; de Ruiter JR; Wiegant WW; Schmid JA; de Bruijn R; James DI; Guerrero Llobet S; Vis DJ; Annunziato S; van den Broek B; Barazas M; Kersbergen A; van de Ven M; Tarsounas M; Ogilvie DJ; van Vugt M; Wessels LFA; Bartkova J; Gromova I; Andújar-Sánchez M; Bartek J; Lopes M; van Attikum H; Borst P; Jonkers J; Rottenberg S
Cancer Cell; 2018 Jun; 33(6):1078-1093.e12. PubMed ID: 29894693
[TBL] [Abstract][Full Text] [Related]
16. Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
De Summa S; Pinto R; Pilato B; Sambiasi D; Porcelli L; Guida G; Mattioli E; Paradiso A; Merla G; Micale L; De Nittis P; Tommasi S
Cell Death Dis; 2014 Feb; 5(2):e1076. PubMed ID: 24556691
[TBL] [Abstract][Full Text] [Related]
17. [Cellular functions of BRCA genes - from basic science to therapeutics].
Miki Y
Gan To Kagaku Ryoho; 2012 Apr; 39(4):498-501. PubMed ID: 22504671
[TBL] [Abstract][Full Text] [Related]
18. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
Ibrahim YH; García-García C; Serra V; He L; Torres-Lockhart K; Prat A; Anton P; Cozar P; Guzmán M; Grueso J; Rodríguez O; Calvo MT; Aura C; Díez O; Rubio IT; Pérez J; Rodón J; Cortés J; Ellisen LW; Scaltriti M; Baselga J
Cancer Discov; 2012 Nov; 2(11):1036-47. PubMed ID: 22915752
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibition as a prototype for synthetic lethal screens.
Liu X
Methods Mol Biol; 2013; 986():123-37. PubMed ID: 23436410
[TBL] [Abstract][Full Text] [Related]
20. Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction.
Carbajosa S; Pansa MF; Paviolo NS; Castellaro AM; Andino DL; Nigra AD; García IA; Racca AC; Rodriguez-Berdini L; Angiolini V; Guantay L; Villafañez F; Federico MB; Rodríguez-Baili MC; Caputto BL; Drewes G; Madauss KP; Gloger I; Fernandez E; Gil GA; Bocco JL; Gottifredi V; Soria G
Clin Cancer Res; 2019 Jul; 25(13):4049-4062. PubMed ID: 30890549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
